nodes	percent_of_prediction	percent_of_DWPC	metapath
Mirabegron—SLCO1A2—Methotrexate—lymphatic system cancer	0.168	0.215	CbGbCtD
Mirabegron—ABCB1—Mitoxantrone—lymphatic system cancer	0.109	0.139	CbGbCtD
Mirabegron—CYP3A4—Cytarabine—lymphatic system cancer	0.0948	0.121	CbGbCtD
Mirabegron—CYP3A4—Teniposide—lymphatic system cancer	0.0934	0.119	CbGbCtD
Mirabegron—ALB—Methotrexate—lymphatic system cancer	0.0869	0.111	CbGbCtD
Mirabegron—ABCB1—Vincristine—lymphatic system cancer	0.075	0.0958	CbGbCtD
Mirabegron—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0653	0.0834	CbGbCtD
Mirabegron—ABCB1—Methotrexate—lymphatic system cancer	0.0454	0.058	CbGbCtD
Mirabegron—CYP3A4—Vincristine—lymphatic system cancer	0.045	0.0574	CbGbCtD
Mirabegron—Neoplasm—Teniposide—lymphatic system cancer	0.00523	0.0241	CcSEcCtD
Mirabegron—Cerebrovascular accident—Fludarabine—lymphatic system cancer	0.00377	0.0174	CcSEcCtD
Mirabegron—Erythema multiforme—Mechlorethamine—lymphatic system cancer	0.00373	0.0172	CcSEcCtD
Mirabegron—Gamma-glutamyltransferase increased—Mitoxantrone—lymphatic system cancer	0.00368	0.0169	CcSEcCtD
Mirabegron—Cystitis noninfective—Bleomycin—lymphatic system cancer	0.00364	0.0168	CcSEcCtD
Mirabegron—Cystitis—Bleomycin—lymphatic system cancer	0.0036	0.0166	CcSEcCtD
Mirabegron—Bladder pain—Bleomycin—lymphatic system cancer	0.00337	0.0155	CcSEcCtD
Mirabegron—Leukocytoclastic vasculitis—Methotrexate—lymphatic system cancer	0.00307	0.0142	CcSEcCtD
Mirabegron—Upper respiratory tract infection—Fludarabine—lymphatic system cancer	0.00296	0.0137	CcSEcCtD
Mirabegron—Neoplasm—Carmustine—lymphatic system cancer	0.00294	0.0136	CcSEcCtD
Mirabegron—Unspecified disorder of skin and subcutaneous tissue—Mechlorethamine—lymphatic system cancer	0.0029	0.0134	CcSEcCtD
Mirabegron—Stevens-Johnson syndrome—Fludarabine—lymphatic system cancer	0.00282	0.013	CcSEcCtD
Mirabegron—Infection—Mechlorethamine—lymphatic system cancer	0.00278	0.0128	CcSEcCtD
Mirabegron—Urinary tract infection—Fludarabine—lymphatic system cancer	0.00276	0.0127	CcSEcCtD
Mirabegron—Cerebrovascular accident—Bleomycin—lymphatic system cancer	0.00276	0.0127	CcSEcCtD
Mirabegron—Skin disorder—Mechlorethamine—lymphatic system cancer	0.00272	0.0125	CcSEcCtD
Mirabegron—Sinusitis—Fludarabine—lymphatic system cancer	0.00267	0.0123	CcSEcCtD
Mirabegron—Erythema multiforme—Fludarabine—lymphatic system cancer	0.00241	0.0111	CcSEcCtD
Mirabegron—Hypertension—Teniposide—lymphatic system cancer	0.00218	0.0101	CcSEcCtD
Mirabegron—Urinary retention—Vincristine—lymphatic system cancer	0.00214	0.00988	CcSEcCtD
Mirabegron—Infection—Teniposide—lymphatic system cancer	0.00205	0.00945	CcSEcCtD
Mirabegron—Aspartate aminotransferase increased—Vincristine—lymphatic system cancer	0.00203	0.00936	CcSEcCtD
Mirabegron—Tachycardia—Teniposide—lymphatic system cancer	0.00201	0.00928	CcSEcCtD
Mirabegron—Pruritus—Mechlorethamine—lymphatic system cancer	0.00198	0.00913	CcSEcCtD
Mirabegron—Aspartate aminotransferase increased—Mitoxantrone—lymphatic system cancer	0.00198	0.00911	CcSEcCtD
Mirabegron—Alanine aminotransferase increased—Mitoxantrone—lymphatic system cancer	0.00194	0.00892	CcSEcCtD
Mirabegron—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00192	0.00883	CcSEcCtD
Mirabegron—Arthralgia—Fludarabine—lymphatic system cancer	0.00189	0.00872	CcSEcCtD
Mirabegron—Infection—Fludarabine—lymphatic system cancer	0.0018	0.0083	CcSEcCtD
Mirabegron—Urinary tract infection—Carmustine—lymphatic system cancer	0.00177	0.00815	CcSEcCtD
Mirabegron—Rash—Mechlorethamine—lymphatic system cancer	0.00177	0.00813	CcSEcCtD
Mirabegron—Upper respiratory tract infection—Mitoxantrone—lymphatic system cancer	0.00176	0.00813	CcSEcCtD
Mirabegron—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00176	0.00813	CcSEcCtD
Mirabegron—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00169	0.00778	CcSEcCtD
Mirabegron—Nausea—Mechlorethamine—lymphatic system cancer	0.00166	0.00766	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00165	0.00761	CcSEcCtD
Mirabegron—Urinary tract infection—Mitoxantrone—lymphatic system cancer	0.00165	0.00758	CcSEcCtD
Mirabegron—Urticaria—Teniposide—lymphatic system cancer	0.00164	0.00755	CcSEcCtD
Mirabegron—Abdominal pain—Teniposide—lymphatic system cancer	0.00163	0.00752	CcSEcCtD
Mirabegron—Connective tissue disorder—Carmustine—lymphatic system cancer	0.00161	0.0074	CcSEcCtD
Mirabegron—Dyspepsia—Fludarabine—lymphatic system cancer	0.0016	0.00736	CcSEcCtD
Mirabegron—Sinusitis—Mitoxantrone—lymphatic system cancer	0.00159	0.00732	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00157	0.00722	CcSEcCtD
Mirabegron—Fatigue—Fludarabine—lymphatic system cancer	0.00156	0.00721	CcSEcCtD
Mirabegron—Constipation—Fludarabine—lymphatic system cancer	0.00155	0.00715	CcSEcCtD
Mirabegron—Urinary tract disorder—Vincristine—lymphatic system cancer	0.00154	0.0071	CcSEcCtD
Mirabegron—Connective tissue disorder—Vincristine—lymphatic system cancer	0.00153	0.00706	CcSEcCtD
Mirabegron—Urethral disorder—Vincristine—lymphatic system cancer	0.00153	0.00705	CcSEcCtD
Mirabegron—Eye disorder—Carmustine—lymphatic system cancer	0.00153	0.00704	CcSEcCtD
Mirabegron—Rhinitis—Mitoxantrone—lymphatic system cancer	0.00152	0.00702	CcSEcCtD
Mirabegron—Asthenia—Teniposide—lymphatic system cancer	0.00148	0.00682	CcSEcCtD
Mirabegron—Cystitis noninfective—Methotrexate—lymphatic system cancer	0.00147	0.00678	CcSEcCtD
Mirabegron—Pruritus—Teniposide—lymphatic system cancer	0.00146	0.00673	CcSEcCtD
Mirabegron—Cystitis—Methotrexate—lymphatic system cancer	0.00146	0.00671	CcSEcCtD
Mirabegron—Cardiac disorder—Vincristine—lymphatic system cancer	0.00145	0.00667	CcSEcCtD
Mirabegron—Vaginal infection—Methotrexate—lymphatic system cancer	0.00142	0.00656	CcSEcCtD
Mirabegron—Diarrhoea—Teniposide—lymphatic system cancer	0.00141	0.00651	CcSEcCtD
Mirabegron—Back pain—Carmustine—lymphatic system cancer	0.00138	0.00634	CcSEcCtD
Mirabegron—Neoplasm—Methotrexate—lymphatic system cancer	0.00136	0.00628	CcSEcCtD
Mirabegron—Bladder pain—Methotrexate—lymphatic system cancer	0.00136	0.00628	CcSEcCtD
Mirabegron—Vision blurred—Carmustine—lymphatic system cancer	0.00134	0.00618	CcSEcCtD
Mirabegron—Infection—Bleomycin—lymphatic system cancer	0.00132	0.00609	CcSEcCtD
Mirabegron—Back pain—Vincristine—lymphatic system cancer	0.00131	0.00605	CcSEcCtD
Mirabegron—Asthenia—Fludarabine—lymphatic system cancer	0.0013	0.006	CcSEcCtD
Mirabegron—Rash—Teniposide—lymphatic system cancer	0.0013	0.006	CcSEcCtD
Mirabegron—Dermatitis—Teniposide—lymphatic system cancer	0.0013	0.00599	CcSEcCtD
Mirabegron—Headache—Teniposide—lymphatic system cancer	0.00129	0.00596	CcSEcCtD
Mirabegron—Pruritus—Fludarabine—lymphatic system cancer	0.00128	0.00591	CcSEcCtD
Mirabegron—Back pain—Mitoxantrone—lymphatic system cancer	0.00128	0.00589	CcSEcCtD
Mirabegron—Vision blurred—Mitoxantrone—lymphatic system cancer	0.00125	0.00574	CcSEcCtD
Mirabegron—Diarrhoea—Fludarabine—lymphatic system cancer	0.00124	0.00572	CcSEcCtD
Mirabegron—Hypertension—Carmustine—lymphatic system cancer	0.00123	0.00566	CcSEcCtD
Mirabegron—Nausea—Teniposide—lymphatic system cancer	0.00123	0.00565	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00121	0.00558	CcSEcCtD
Mirabegron—Hypertension—Vincristine—lymphatic system cancer	0.00117	0.0054	CcSEcCtD
Mirabegron—Infection—Carmustine—lymphatic system cancer	0.00115	0.00531	CcSEcCtD
Mirabegron—Rash—Fludarabine—lymphatic system cancer	0.00114	0.00527	CcSEcCtD
Mirabegron—Dermatitis—Fludarabine—lymphatic system cancer	0.00114	0.00526	CcSEcCtD
Mirabegron—Hypertension—Mitoxantrone—lymphatic system cancer	0.00114	0.00526	CcSEcCtD
Mirabegron—Headache—Fludarabine—lymphatic system cancer	0.00114	0.00524	CcSEcCtD
Mirabegron—Tachycardia—Carmustine—lymphatic system cancer	0.00113	0.00522	CcSEcCtD
Mirabegron—Arthralgia—Mitoxantrone—lymphatic system cancer	0.00113	0.00519	CcSEcCtD
Mirabegron—Cerebrovascular accident—Methotrexate—lymphatic system cancer	0.00112	0.00514	CcSEcCtD
Mirabegron—Infection—Vincristine—lymphatic system cancer	0.0011	0.00507	CcSEcCtD
Mirabegron—Osteoarthritis—Methotrexate—lymphatic system cancer	0.00109	0.00504	CcSEcCtD
Mirabegron—Nausea—Fludarabine—lymphatic system cancer	0.00108	0.00496	CcSEcCtD
Mirabegron—Infection—Mitoxantrone—lymphatic system cancer	0.00107	0.00494	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00106	0.00487	CcSEcCtD
Mirabegron—Urticaria—Bleomycin—lymphatic system cancer	0.00106	0.00487	CcSEcCtD
Mirabegron—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00105	0.00485	CcSEcCtD
Mirabegron—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00105	0.00483	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00101	0.00465	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.001	0.00462	CcSEcCtD
Mirabegron—Constipation—Carmustine—lymphatic system cancer	0.000993	0.00457	CcSEcCtD
Mirabegron—Breast disorder—Methotrexate—lymphatic system cancer	0.000989	0.00456	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000983	0.00453	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000957	0.00441	CcSEcCtD
Mirabegron—Fatigue—Vincristine—lymphatic system cancer	0.000956	0.0044	CcSEcCtD
Mirabegron—Asthenia—Bleomycin—lymphatic system cancer	0.000954	0.0044	CcSEcCtD
Mirabegron—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00095	0.00438	CcSEcCtD
Mirabegron—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000949	0.00437	CcSEcCtD
Mirabegron—Constipation—Vincristine—lymphatic system cancer	0.000948	0.00437	CcSEcCtD
Mirabegron—Pruritus—Bleomycin—lymphatic system cancer	0.000941	0.00434	CcSEcCtD
Mirabegron—Fatigue—Mitoxantrone—lymphatic system cancer	0.000931	0.00429	CcSEcCtD
Mirabegron—Constipation—Mitoxantrone—lymphatic system cancer	0.000923	0.00425	CcSEcCtD
Mirabegron—Abdominal pain—Carmustine—lymphatic system cancer	0.000918	0.00423	CcSEcCtD
Mirabegron—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000906	0.00418	CcSEcCtD
Mirabegron—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000883	0.00407	CcSEcCtD
Mirabegron—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.000879	0.00405	CcSEcCtD
Mirabegron—Abdominal pain—Vincristine—lymphatic system cancer	0.000876	0.00404	CcSEcCtD
Mirabegron—Urticaria—Mitoxantrone—lymphatic system cancer	0.000857	0.00395	CcSEcCtD
Mirabegron—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000853	0.00393	CcSEcCtD
Mirabegron—Infestation NOS—Methotrexate—lymphatic system cancer	0.000843	0.00388	CcSEcCtD
Mirabegron—Infestation—Methotrexate—lymphatic system cancer	0.000843	0.00388	CcSEcCtD
Mirabegron—Rash—Bleomycin—lymphatic system cancer	0.000839	0.00386	CcSEcCtD
Mirabegron—Dermatitis—Bleomycin—lymphatic system cancer	0.000838	0.00386	CcSEcCtD
Mirabegron—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.000836	0.00385	CcSEcCtD
Mirabegron—Asthenia—Carmustine—lymphatic system cancer	0.000833	0.00384	CcSEcCtD
Mirabegron—Asthenia—Vincristine—lymphatic system cancer	0.000795	0.00366	CcSEcCtD
Mirabegron—Diarrhoea—Carmustine—lymphatic system cancer	0.000794	0.00366	CcSEcCtD
Mirabegron—Nausea—Bleomycin—lymphatic system cancer	0.00079	0.00364	CcSEcCtD
Mirabegron—Asthenia—Mitoxantrone—lymphatic system cancer	0.000774	0.00357	CcSEcCtD
Mirabegron—Dizziness—Carmustine—lymphatic system cancer	0.000768	0.00354	CcSEcCtD
Mirabegron—Diarrhoea—Vincristine—lymphatic system cancer	0.000758	0.00349	CcSEcCtD
Mirabegron—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000748	0.00344	CcSEcCtD
Mirabegron—Urethral disorder—Methotrexate—lymphatic system cancer	0.000742	0.00342	CcSEcCtD
Mirabegron—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000739	0.0034	CcSEcCtD
Mirabegron—Dizziness—Vincristine—lymphatic system cancer	0.000733	0.00338	CcSEcCtD
Mirabegron—Rash—Carmustine—lymphatic system cancer	0.000732	0.00337	CcSEcCtD
Mirabegron—Dermatitis—Carmustine—lymphatic system cancer	0.000731	0.00337	CcSEcCtD
Mirabegron—Headache—Carmustine—lymphatic system cancer	0.000727	0.00335	CcSEcCtD
Mirabegron—Erythema multiforme—Methotrexate—lymphatic system cancer	0.000716	0.0033	CcSEcCtD
Mirabegron—Eye disorder—Methotrexate—lymphatic system cancer	0.000707	0.00326	CcSEcCtD
Mirabegron—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000703	0.00324	CcSEcCtD
Mirabegron—Rash—Vincristine—lymphatic system cancer	0.000699	0.00322	CcSEcCtD
Mirabegron—Dermatitis—Vincristine—lymphatic system cancer	0.000698	0.00322	CcSEcCtD
Mirabegron—Headache—Vincristine—lymphatic system cancer	0.000694	0.0032	CcSEcCtD
Mirabegron—Nausea—Carmustine—lymphatic system cancer	0.00069	0.00318	CcSEcCtD
Mirabegron—Rash—Mitoxantrone—lymphatic system cancer	0.000681	0.00314	CcSEcCtD
Mirabegron—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00068	0.00313	CcSEcCtD
Mirabegron—Headache—Mitoxantrone—lymphatic system cancer	0.000676	0.00312	CcSEcCtD
Mirabegron—Nausea—Vincristine—lymphatic system cancer	0.000658	0.00303	CcSEcCtD
Mirabegron—Nausea—Mitoxantrone—lymphatic system cancer	0.000641	0.00295	CcSEcCtD
Mirabegron—Back pain—Methotrexate—lymphatic system cancer	0.000637	0.00294	CcSEcCtD
Mirabegron—Vision blurred—Methotrexate—lymphatic system cancer	0.000621	0.00286	CcSEcCtD
Mirabegron—Arthralgia—Methotrexate—lymphatic system cancer	0.000561	0.00258	CcSEcCtD
Mirabegron—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000557	0.00257	CcSEcCtD
Mirabegron—Infection—Methotrexate—lymphatic system cancer	0.000534	0.00246	CcSEcCtD
Mirabegron—Skin disorder—Methotrexate—lymphatic system cancer	0.000522	0.00241	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.00049	0.00226	CcSEcCtD
Mirabegron—Dyspepsia—Methotrexate—lymphatic system cancer	0.000473	0.00218	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000464	0.00214	CcSEcCtD
Mirabegron—Fatigue—Methotrexate—lymphatic system cancer	0.000464	0.00214	CcSEcCtD
Mirabegron—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.00044	0.00203	CcSEcCtD
Mirabegron—Urticaria—Methotrexate—lymphatic system cancer	0.000427	0.00197	CcSEcCtD
Mirabegron—Abdominal pain—Methotrexate—lymphatic system cancer	0.000425	0.00196	CcSEcCtD
Mirabegron—Asthenia—Methotrexate—lymphatic system cancer	0.000386	0.00178	CcSEcCtD
Mirabegron—Pruritus—Methotrexate—lymphatic system cancer	0.00038	0.00175	CcSEcCtD
Mirabegron—Diarrhoea—Methotrexate—lymphatic system cancer	0.000368	0.0017	CcSEcCtD
Mirabegron—Dizziness—Methotrexate—lymphatic system cancer	0.000356	0.00164	CcSEcCtD
Mirabegron—Rash—Methotrexate—lymphatic system cancer	0.000339	0.00156	CcSEcCtD
Mirabegron—Dermatitis—Methotrexate—lymphatic system cancer	0.000339	0.00156	CcSEcCtD
Mirabegron—Headache—Methotrexate—lymphatic system cancer	0.000337	0.00155	CcSEcCtD
Mirabegron—Nausea—Methotrexate—lymphatic system cancer	0.000319	0.00147	CcSEcCtD
